Familial dermatographia

Summary

Familial dermatographia (MONDO:0007448) is a disease. A subtype of physical urticaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	familial dermatographia
Mondo ID	MONDO:0007448
EFO	EFO:1000685
MeSH	C536612
OMIM	125635
DOID	DOID:743
ICD-10-CM	L50.3
SNOMED CT	7632005
UMLS	C1852145
MedGen	342170
Is cancer (heuristic)	no

Also known as: DDU · dermatographia · dermatographic urticaria · Dermatographism, familial · dermo-distortive urticaria · Dermodistortive urticaria · dermographism · dermographism, familial · familial dermatographism · familial dermographism · VBU · vibratory angioedema · vibratory urticaria

Disease family

This is a subtype of physical urticaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › urticaria › physical urticaria › familial dermatographia

Related subtypes (2): cholinergic urticaria, vibratory urticaria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Omalizumab	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 0.